share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali

CRISPR Therapeutics | 4：持股变动声明-董事 Behbahani Ali
美股sec公告 ·  05/31 16:54
Moomoo AI 已提取核心信息
In a recent transaction, Ali Behbahani, a reporting person for CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The details of the transaction, including the number of shares involved, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed. The relationship of Behbahani to the issuer was not specified in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
In a recent transaction, Ali Behbahani, a reporting person for CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The details of the transaction, including the number of shares involved, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed. The relationship of Behbahani to the issuer was not specified in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
在最近的一笔交易中，CRISPR Therapeutics AG（CRSP）的举报人阿里·贝巴哈尼于2024年5月30日执行了一笔股票交易。该交易的细节，包括所涉及的股票数量、股票的性质、交易价格和股票的总价值，尚未披露。公告中没有具体说明Behbahani与发行人的关系。建议投资者注意交易日期，以了解对股票表现的任何潜在影响。
在最近的一笔交易中，CRISPR Therapeutics AG（CRSP）的举报人阿里·贝巴哈尼于2024年5月30日执行了一笔股票交易。该交易的细节，包括所涉及的股票数量、股票的性质、交易价格和股票的总价值，尚未披露。公告中没有具体说明Behbahani与发行人的关系。建议投资者注意交易日期，以了解对股票表现的任何潜在影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息